Actuate Therapeutics (ACTU) Free Cash Flow (2023 - 2025)
Actuate Therapeutics (ACTU) posted quarterly Free Cash Flow of -$3.7 million for Q4 2025, up 23.49% year-over-year from -$3.0 million in Q4 2024, and up 44.05% quarter-over-quarter from -$6.7 million in Q3 2025.
Actuate Therapeutics (ACTU) Free Cash Flow (2023 - 2025) Analysis & Trends
Actuate Therapeutics (ACTU) has reported Free Cash Flow for 3 consecutive years, with -$3.7 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Free Cash Flow rose 23.49% year-over-year to -$3.7 million; the TTM figure through Dec 2025 stood at -$19.1 million (up 13.02% YoY), while the FY2025 annual figure was -$19.1 million, up 13.02% from the prior year.
- Free Cash Flow improved to -$3.7 million in Q4 2025 per ACTU's latest filing, from -$6.7 million in the prior quarter.
- Across five years, Free Cash Flow topped out at -$2.7 million in Q2 2024 and bottomed at -$9.1 million in Q3 2024.
- Historically, Free Cash Flow has averaged -$5.2 million across 3 years, with a median of -$5.1 million in 2024.
- Annual changes were most pronounced in 2024 — Free Cash Flow sank 62.27% — and 2025, when it climbed 27.01%.
- Actuate Therapeutics' Free Cash Flow stood at -$5.5 million in 2023, then rose by 11.41% to -$4.9 million in 2024, then advanced by 23.49% to -$3.7 million in 2025.
- Business Quant data shows ACTU's Free Cash Flow at -$3.7 million in Q4 2025, -$6.7 million in Q3 2025, and -$4.2 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -563.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 437.80 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 292.04 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 433.84 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -95.09 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 477.44 Mn |
| 10 | Actuate Therapeutics | 30.08 Mn | 30.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.74 Mn |
| Dec 31, 2025 | -3.74 Mn |
| Sep 30, 2025 | -6.68 Mn |
| Sep 30, 2025 | -6.68 Mn |
| Jun 30, 2025 | -4.17 Mn |
| Jun 30, 2025 | -4.17 Mn |
| Mar 31, 2025 | -4.51 Mn |
| Mar 31, 2025 | -4.51 Mn |
| Dec 31, 2024 | -4.88 Mn |
| Dec 31, 2024 | -4.88 Mn |
| Sep 30, 2024 | -9.15 Mn |
| Sep 30, 2024 | -9.15 Mn |
| Jun 30, 2024 | -2.67 Mn |
| Jun 30, 2024 | -2.67 Mn |
| Mar 31, 2024 | -5.25 Mn |
| Mar 31, 2024 | -5.25 Mn |
| Dec 31, 2023 | -5.51 Mn |
| Dec 31, 2023 | -5.51 Mn |
| Sep 30, 2023 | -5.64 Mn |
| Sep 30, 2023 | -5.64 Mn |